Abstract
Background Randomized control trials (RCT) of ultrafiltration (UF) have demonstrated conflicting results regarding its efficacy and safety. We reviewed 10 years of real world data regarding UF during hospitalization for ADHF. Methods and Results We performed a retrospective, single center analysis of 335 consecutive patients treated with adjustable rate UF using the CHF Solutions Aquadex Flex Flo System from 7/28/2009 to 6/30/2019. UF for all patients was managed solely by the HF service. Compared to previous RCTs investigating UF, our cohort was older, with worse renal function, and more antecedent HF hospitalizations in the year preceding therapy. Patient characteristics were as follows: mean age 73, 57% male, 48% LVEF Conclusions Compared with previous trials with UF (UNLOAD, CARRESS and AVOID), our real world experience demonstrates that UF compares favorably for HF re-hospitalizations, renal function response, and weight /volume loss. Our cohort was sicker than those studied in clinical trials. Importantly, our real world experience allowed for the adjustment of UF rate during therapy, and we believe this to be a major contributor to our favorable outcomes. In clinical practice, UF can be a safe and effective strategy for decongestion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
